WO2009103741A3 - Use of fsh receptor ligands for diagnosis and therapy of cancer - Google Patents

Use of fsh receptor ligands for diagnosis and therapy of cancer Download PDF

Info

Publication number
WO2009103741A3
WO2009103741A3 PCT/EP2009/051931 EP2009051931W WO2009103741A3 WO 2009103741 A3 WO2009103741 A3 WO 2009103741A3 EP 2009051931 W EP2009051931 W EP 2009051931W WO 2009103741 A3 WO2009103741 A3 WO 2009103741A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
therapy
diagnosis
fsh receptor
receptor ligands
Prior art date
Application number
PCT/EP2009/051931
Other languages
French (fr)
Other versions
WO2009103741A2 (en
Inventor
Nicolae Ghinea
Aurelian Radu
Original Assignee
Inserm (Institut National De La Sante Et De La Recherche Medicale)
Mount Sinai School Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inserm (Institut National De La Sante Et De La Recherche Medicale), Mount Sinai School Of Medicine filed Critical Inserm (Institut National De La Sante Et De La Recherche Medicale)
Priority to EP09711579.4A priority Critical patent/EP2250504B1/en
Priority to JP2010547171A priority patent/JP5674478B2/en
Priority to US12/866,519 priority patent/US8784776B2/en
Priority to EP13157421.2A priority patent/EP2599504B1/en
Publication of WO2009103741A2 publication Critical patent/WO2009103741A2/en
Publication of WO2009103741A3 publication Critical patent/WO2009103741A3/en
Priority to US14/334,029 priority patent/US9200076B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Optics & Photonics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to diagnostic imaging and in particular to the diagnostic imaging and therapy of cancer by means of compositions which specifically target the FSH Receptor expressed by tumor endothelial cells and circulating blood cells.
PCT/EP2009/051931 2008-02-18 2009-02-18 Use of fsh receptor ligands for diagnosis and therapy of cancer WO2009103741A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP09711579.4A EP2250504B1 (en) 2008-02-18 2009-02-18 Method of detecting or imaging expression of fsh receptor on blood vessels associated with a tumor in a patient
JP2010547171A JP5674478B2 (en) 2008-02-18 2009-02-18 Use of FSH receptor ligands for the diagnosis and treatment of cancer
US12/866,519 US8784776B2 (en) 2008-02-18 2009-02-18 Use of FSH receptor ligands for diagnosis and therapy of cancer
EP13157421.2A EP2599504B1 (en) 2008-02-18 2009-02-18 Use of conjugates of fsh receptor ligands and antitumour agents for therapy of cancer
US14/334,029 US9200076B2 (en) 2008-02-18 2014-07-17 Use of FSH receptor ligands for diagnosis and therapy of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08305026.0 2008-02-18
EP08305026A EP2090322A1 (en) 2008-02-18 2008-02-18 Use of fsh receptor ligands for diagnosis and therapy of cancer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/866,519 A-371-Of-International US8784776B2 (en) 2008-02-18 2009-02-18 Use of FSH receptor ligands for diagnosis and therapy of cancer
US14/334,029 Division US9200076B2 (en) 2008-02-18 2014-07-17 Use of FSH receptor ligands for diagnosis and therapy of cancer

Publications (2)

Publication Number Publication Date
WO2009103741A2 WO2009103741A2 (en) 2009-08-27
WO2009103741A3 true WO2009103741A3 (en) 2010-01-21

Family

ID=39467540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/051931 WO2009103741A2 (en) 2008-02-18 2009-02-18 Use of fsh receptor ligands for diagnosis and therapy of cancer

Country Status (5)

Country Link
US (2) US8784776B2 (en)
EP (3) EP2090322A1 (en)
JP (1) JP5674478B2 (en)
ES (1) ES2778854T3 (en)
WO (1) WO2009103741A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130131136A1 (en) * 2010-08-02 2013-05-23 Nicolae Ghinea Novel methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor
FR2964744B1 (en) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines PROGNOSTIC TEST OF THE EVOLUTION OF A SOLID TUMOR BY ANALYSIS OF IMAGES
US10035009B2 (en) 2013-04-15 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treating pancreatic cancer
WO2014179678A1 (en) * 2013-05-03 2014-11-06 Angiostrass Llc Methods of treating cancer and angioproliferative disorders
EP3200815B1 (en) 2014-10-02 2021-03-03 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
US10538568B2 (en) * 2014-11-04 2020-01-21 The Trustees Of The University Of Pennsylvania Methods and compositions of a follicle stimulating hormone receptor immunoreceptor
IT201600101852A1 (en) * 2016-10-11 2018-04-11 Abresearch Srl FSH hormone receptor ligands in the diagnosis and treatment of tumors
IT201600101870A1 (en) * 2016-10-11 2018-04-11 Abresearch Srl FSH hormone receptor ligands in the diagnosis and therapy of neuroblastoma
JP7226803B2 (en) * 2016-10-11 2023-02-21 オンコグリーン セラピューティクス エッセア Ligands for FSH hormone receptors in tumor diagnosis and therapy
IT201600101862A1 (en) * 2016-10-11 2018-04-11 Abresearch Srl FSH hormone receptor ligands in the diagnosis and treatment of tumors
EP3378872A1 (en) * 2017-03-20 2018-09-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antibodies against the human fshr extracellular domain
EP4380597A1 (en) * 2021-08-04 2024-06-12 FSHR Théranostics Use of fsh-receptor ligands for diagnosis and therapy of atherosclerosis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359347A2 (en) * 1988-08-15 1990-03-21 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
WO1993019668A1 (en) * 1992-04-07 1993-10-14 Immunomedics, Inc. Method and kit for imaging and treating organs and tissues
WO1995015118A1 (en) * 1993-11-30 1995-06-08 Imarx Pharmaceutical Corp. Gas microspheres for topical and subcutaneous application
WO2002009705A2 (en) * 2000-07-31 2002-02-07 Smithkline Beecham Corporation Agonist of follicle stimulating hormone activity
WO2007011434A2 (en) * 2005-07-14 2007-01-25 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
WO2007021621A2 (en) * 2005-08-09 2007-02-22 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College In vivo imaging and therapy with magnetic nanoparticle conjugates

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
IN172208B (en) 1990-04-02 1993-05-01 Sint Sa
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
PT711179E (en) 1993-07-30 2005-03-31 Imcor Pharmaceutical Company STABILIZED MICROBOLHES COMPOSITIONS FOR ULTRASOUND
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
ATE237362T1 (en) 1996-02-19 2003-05-15 Amersham Health As THERMOSTABILIZED CONTRAST AGENT
US20070128117A1 (en) 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
DE602004029010D1 (en) 2003-02-04 2010-10-21 Bracco Suisse Sa ULTRASONIC CONTRASTING AGENT AND METHOD OF CREATION
WO2005087765A1 (en) * 2004-03-04 2005-09-22 Arena Pharmaceuticals, Inc. Ligands of follicle stimulating hormone receptor and methods of use thereof
EP1714642A1 (en) * 2005-04-18 2006-10-25 Bracco Research S.A. Pharmaceutical composition comprising gas-filled microcapsules for ultrasound mediated delivery

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359347A2 (en) * 1988-08-15 1990-03-21 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
WO1993019668A1 (en) * 1992-04-07 1993-10-14 Immunomedics, Inc. Method and kit for imaging and treating organs and tissues
WO1995015118A1 (en) * 1993-11-30 1995-06-08 Imarx Pharmaceutical Corp. Gas microspheres for topical and subcutaneous application
WO2002009705A2 (en) * 2000-07-31 2002-02-07 Smithkline Beecham Corporation Agonist of follicle stimulating hormone activity
WO2007011434A2 (en) * 2005-07-14 2007-01-25 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
WO2007021621A2 (en) * 2005-08-09 2007-02-22 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College In vivo imaging and therapy with magnetic nanoparticle conjugates

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEN-JOSEF ET AL: "HORMONE-REFRACTORY PROSTATE CANCER CELLS EXPRESS FUNCTIONAL FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR)", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 161, no. 3, 1 March 1999 (1999-03-01), pages 970 - 976, XP005562797, ISSN: 0022-5347 *
CHOI J -H ET AL: "Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM 200411 US, vol. 89, no. 11, November 2004 (2004-11-01), pages 5508 - 5516, XP002484160, ISSN: 0021-972X *
LI ET AL: "FSH stimulates ovarian cancer cell growth by action on growth factor variant receptor", MOLECULAR AND CELLULAR ENDOCRINOLOGY, AMSTERDAM, vol. 267, no. 1-2, 28 February 2007 (2007-02-28), pages 26 - 37, XP005915081, ISSN: 0303-7207 *
MARIANI ET AL: "Expression and Cellular Localization of Follicle-Stimulating Hormone Receptor in Normal Human Prostate, Benign Prostatic Hyperplasia and Prostate Cancer", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 175, no. 6, 1 June 2006 (2006-06-01), pages 2072 - 2077, XP005488074, ISSN: 0022-5347 *

Also Published As

Publication number Publication date
EP2599504B1 (en) 2020-01-08
US20100316572A1 (en) 2010-12-16
ES2778854T3 (en) 2020-08-12
JP2011518768A (en) 2011-06-30
US20140328758A1 (en) 2014-11-06
EP2599504A3 (en) 2013-07-31
US8784776B2 (en) 2014-07-22
WO2009103741A2 (en) 2009-08-27
EP2599504A2 (en) 2013-06-05
US9200076B2 (en) 2015-12-01
JP5674478B2 (en) 2015-02-25
EP2250504A2 (en) 2010-11-17
EP2090322A1 (en) 2009-08-19
EP2250504B1 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
WO2009103741A3 (en) Use of fsh receptor ligands for diagnosis and therapy of cancer
WO2010081001A3 (en) Recurrent gene fusions in cancer
WO2013089882A3 (en) Recurrent gene fusions in breast cancer
WO2011034906A3 (en) Recurrent gene fusions in prostate cancer
WO2012068383A3 (en) ncRNA AND USES THEREOF
WO2012174256A3 (en) Dna methylation profiles in cancer
EP3466416A3 (en) A binding moiety-drug conjugate comprising a hsp90 binding moiety and a cytotoxic effector moiety
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2012158780A3 (en) Lung cancer signature
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
WO2011008696A3 (en) Diagnostic methods and compositions for treatment of cancer
WO2010066803A3 (en) Human antibodies against human tissue factor
WO2012074840A3 (en) Compositions and methods for in vivo imaging
MX340295B (en) Monoclonal antibodies against c-met.
WO2014026768A8 (en) Colorectal cancer markers
WO2011028334A3 (en) Synthesis and isolation of dendrimer systems
IN2014KN02933A (en)
WO2007149456A3 (en) Methods and compositions for diagnostic and therapeutic targeting of cox-2
EP3064509A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
PH12015500252A1 (en) Niclosamide for the treatment of solid tumors
IL206748A (en) Molecular probes for the in vitro diagnosis of breast cancer
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2015066053A8 (en) Targeted therapeutics
CA2835730C (en) Molecular markers in prostate cancer
WO2012143481A3 (en) Prostate cancer markers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09711579

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12866519

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2010547171

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009711579

Country of ref document: EP